Jacques Izopet

Jacques Izopet is presented as a specialist in the virology of hepatitis C virus infection within the clinical and research network studying chronic kidney disease, dialysis, and kidney transplantation. His documented role is that of a co-author of the chapter on treatment after kidney transplantation, where virological expertise is joined to nephrology, dialysis, and organ-transplant practice. The book therefore positions him less as a character in a personal narrative than as a named participant in the production and organization of specialist medical knowledge.

Identity and Professional Setting

Jacques Izopet is affiliated with the Laboratory of Virology at Toulouse University Hospital and with INSERM U563, IFR 30. The chapter also associates him with the Department of Nephrology, Dialysis, and Organ Transplantation at CHU Rangueil and Toulouse University Hospital through the author team led by Lionel Rostaing. This institutional setting matters because the subject is not HCV infection in isolation: it is the interaction among viral persistence, immunosuppression, liver injury, renal disease, and the survival of a transplanted kidney.

His position links laboratory identification to bedside decisions. Elsewhere in the volume, chronic HCV infection is defined by the simultaneous presence of anti-HCV antibodies and detectable HCV RNA, while the wider clinical discussion treats the infection as systemic, capable of producing hepatic, autoimmune, dermatological, and renal disease. Izopet’s placement in a virology laboratory gives that diagnostic boundary particular importance: antibody positivity alone does not establish active infection, whereas molecular detection of HCV RNA distinguishes ongoing infection from resolved disease.

Work on HCV After Kidney Transplantation

Izopet’s principal documented contribution concerns treatment of HCV infection after kidney transplantation. The chapter explains that antiviral therapy may be considered to prevent or reduce HCV-related liver injury and may also be used when HCV-positive kidney-transplant recipients develop de novo cryoglobulinemic membranoproliferative glomerulonephritis in the renal allograft. In that setting, clearing HCV from serum is not merely a virological endpoint; it is presented as a means of reducing continuing renal injury.

The chapter’s treatment history gives his subject a sharply practical dimension. Early post-transplant studies of standard alpha interferon, administered at 3–10 million units three times weekly, produced disappointing results: aminotransferase levels improved in only about half of cases, on-treatment virological response was approximately 25 percent, sustained virological response was very low, and adverse effects caused many patients to discontinue therapy. Most seriously, acute renal failure was associated with acute-rejection episodes and, in some cases, loss of the graft. Later evidence indicated that many of these rejection episodes were humoral in type.

The synthesis of this evidence leads to a clear caution about post-transplant interferon. A meta-analysis of 12 clinical trials involving 102 unique renal-transplant patients estimated sustained virological response at 18 percent and treatment dropout at 35 percent; graft dysfunction was the most frequent adverse effect requiring interruption, accounting for 28 cases and 71.7 percent of such interruptions. The chapter therefore recommends against alpha interferon or pegylated alpha interferon alone in HCV-positive kidney-transplant recipients, framing treatment choice as a balance between viral clearance and protection of the renal allograft.

Renal Complications and Therapeutic Choices

Izopet’s documented subject also includes the connection between HCV and post-transplant renal pathology. Cryoglobulinemia is reported as particularly common among HCV-positive kidney-transplant recipients and may produce heavy proteinuria and allograft dysfunction. In a series of seven patients with type III cryoglobulinemia-associated membranoproliferative glomerulonephritis, five were HCV-positive; the clinical picture included impaired renal function long after transplantation, de novo nephrotic syndrome in five patients, severe hypertension in five, nephritic syndrome in one, and increased serum creatinine in one.

For this complication, the chapter describes rituximab as a possible treatment rather than presenting it as risk-free. Weekly infusions at 375 mg/m2 were given for two, three, or four weeks. Renal parameters improved dramatically: nephrotic syndrome entered sustained remission in three cases, nephritic syndrome disappeared in one, nephrotic syndrome improved in two, and cryoglobulins were cleared sustainably in six. Severe infectious complications nevertheless occurred in two cases, preserving the central tension of transplant medicine between suppressing pathogenic antibody activity and exposing an immunosuppressed recipient to infection.

The chapter’s final therapeutic position is conditional. Pegylated alpha interferon plus ribavirin is considered reasonable for recipients who develop severe liver fibrosis after transplantation or fibrosing cholestatic hepatitis. Rituximab may be attempted in recipients with cryoglobulinemia-related membranoproliferative glomerulonephritis and heavy proteinuria. Because interferon can endanger kidney-allograft function, the preferred strategic implication is to eradicate HCV before kidney transplantation whenever possible; treatment before transplantation is described as having efficacy comparable to that in the general population.

Place in the Volume’s Medical Argument

Izopet’s role gains significance from the larger argument of the volume. HCV is described as a worldwide public-health burden affecting more than 150 million people in the preface and approximately 170 million people in the later epidemiological discussion. Its clinical importance extends beyond the liver: in dialysis populations, anti-HCV positivity is associated with increased all-cause mortality, with a meta-analytic relative risk of 1.34 among 11,589 patients and an unadjusted liver-related mortality risk of 5.89. Yet transplantation remains the preferred renal-replacement therapy for infected patients who do not have advanced liver injury, despite the elevated long-term risks associated with infection.

That contrast defines the intellectual space in which Izopet appears. HCV complicates transplantation, but it does not automatically disqualify transplantation; antiviral treatment can protect the liver and potentially the graft, but interferon can itself provoke rejection and graft dysfunction; immunosuppressive therapy can sustain the transplant while intensifying infectious danger. As a virologist embedded in a transplant-oriented research team, Jacques Izopet represents the book’s effort to keep these competing consequences in one frame, translating molecular evidence about viral persistence into decisions about graft survival, renal injury, and the timing of treatment.